The pharma-supply complex largely sat out the AI melt-up — Corning rebounded on optics, Baxter beat and raised, but Eli Lilly's GLP-1 softness dragged the demand anchor as 100% pharma tariffs loom.

Corning topped the vertical at +9.0% to $135.22, but the move belongs to optics, not packaging. Corning reported Q2 on July 28 — core EPS of $0.78 (up 30% year over year), sales of $4.74 billion, Optical Communications up 32% — and fell roughly 14% that day on cautious Q3 guidance; Thursday it clawed the loss back as the AI-interconnect thesis reasserted (NVIDIA's $500 million warrant and Amazon's multi-year procurement anchoring the fiber franchise). Within this vertical Corning matters as the Valor pharmaceutical-glass supplier — a fill-finish chokepoint input — but this session's bid was for its datacenter glass, and it is worth naming that plainly.

The laggard was the vertical's demand anchor. Eli Lilly fell −4.5% to $1,154.97, and not on earnings — Lilly reports August 5. The pressure is GLP-1 competition and slowing momentum for its oral obesity drug: weekly Foundayo (orforglipron) prescriptions have stalled for five straight weeks, and Goldman cut its 2026 U.S. estimate for the franchise to $755 million from $1.1 billion. That matters upstream: GLP-1 volume is the anchor tenant filling the vials, syringes and CDMO lines this vertical maps, so a cooling obesity-pill ramp is a demand signal for the whole fill-finish chain, not just for Lilly.

The pharma-native names that did move told a cleaner story. Baxter jumped +8.0% to $26.75 on a Q2 double beat — revenue of $2.96 billion over the $2.79 billion estimate, adjusted EPS of $0.56 versus $0.37, a raised full-year outlook, and a tariff-refund benefit — a direct read on the sterile-injectables-and-infusion chokepoint. Bachem's ADR rose +4.6%, the peptide-CDMO supply behind the GLP-1 boom. Bioprocessing and tools were mixed and muted (Repligen +1.7%, Maravai +2.4%, Danaher −0.2%, Thermo Fisher +0.1%), as was the glass-and-packaging bench (West +0.6%, Stevanato −1.0%, AptarGroup −1.7%, Gerresheimer's ADR flat) and the China CDMOs (WuXi AppTec −0.6%). The vertical, in short, largely ignored the AI-driven tape ripping through everything else.

The catalyst that dominates the week is policy: Section 232 pharmaceutical tariffs — 100% on patented pharma and APIs — take effect July 31, a direct hit to import-dependent supply and a reshoring tailwind for the domestic fill-finish and API chokepoint. Earnings then arrive in a cluster: Repligen, Waters (its first quarter as the combined Waters/BD entity) and Stevanato on August 4; Novo Nordisk's H1 and Eli Lilly on August 5; Charles River and Amphastar on August 6; and SCHOTT Pharma on August 12.